Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test whether Daratumumab-SC, a drug that eliminates
antibody-producing plasma cells, can effectively lower the level of preformed antibodies in
patients awaiting heart transplantation. These preformed antibodies limit the number of donor
hearts that are compatible for the patients. If Daratumumab-SC can effectively remove
preformed, donor-specific antibodies, then highly allosensitized patients will have more
compatible hearts available to them, potentially decreasing transplant waitlist time and
reducing mortality.